Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products

Takao Hayakawa, Takashi Aoi, Christopher Bravery, Karin Hoogendoorn, Ivana Knezevic, Junichi Koga, Daisuke Maeda, Akifumi Matsuyama, James McBlane, Tomohiro Morio, John Petricciani, Mahendra Rao, Anthony Ridgway, Daisaku Sato, Yoji Sato, Glyn Stacey, Norihisa Sakamoto, Jean Hugues Trouvin, Akihiro Umezawa, Masayuki Yamato & 4 others Kazuo Yano, Hiroyuki Yokote, Kentaro Yoshimatsu, Pierrette Zorzi-Morre

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document.Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted.Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.The conference concluded that most of the current regulatory framework is appropriate for cell therapy, but there are some areas where the application of the requirements for traditional biologicals is inappropriate. In addition, it was agreed that there is a need for international consensus on core regulatory elements, and that one of the major international organizations should take the lead in formulating such a consensus document.

Original languageEnglish
Pages (from-to)283-297
Number of pages15
JournalBiologicals
Volume43
Issue number5
DOIs
Publication statusPublished - 01-09-2015

Fingerprint

Human Development
Cell- and Tissue-Based Therapy
Cells
Acoustic waves
Consensus
Proteins
Industry

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Hayakawa, T., Aoi, T., Bravery, C., Hoogendoorn, K., Knezevic, I., Koga, J., ... Zorzi-Morre, P. (2015). Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products. Biologicals, 43(5), 283-297. https://doi.org/10.1016/j.biologicals.2015.07.009
Hayakawa, Takao ; Aoi, Takashi ; Bravery, Christopher ; Hoogendoorn, Karin ; Knezevic, Ivana ; Koga, Junichi ; Maeda, Daisuke ; Matsuyama, Akifumi ; McBlane, James ; Morio, Tomohiro ; Petricciani, John ; Rao, Mahendra ; Ridgway, Anthony ; Sato, Daisaku ; Sato, Yoji ; Stacey, Glyn ; Sakamoto, Norihisa ; Trouvin, Jean Hugues ; Umezawa, Akihiro ; Yamato, Masayuki ; Yano, Kazuo ; Yokote, Hiroyuki ; Yoshimatsu, Kentaro ; Zorzi-Morre, Pierrette. / Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products. In: Biologicals. 2015 ; Vol. 43, No. 5. pp. 283-297.
@article{16dd6e6bf10a4d248b59112091e9cfce,
title = "Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products",
abstract = "The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document.Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted.Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.The conference concluded that most of the current regulatory framework is appropriate for cell therapy, but there are some areas where the application of the requirements for traditional biologicals is inappropriate. In addition, it was agreed that there is a need for international consensus on core regulatory elements, and that one of the major international organizations should take the lead in formulating such a consensus document.",
author = "Takao Hayakawa and Takashi Aoi and Christopher Bravery and Karin Hoogendoorn and Ivana Knezevic and Junichi Koga and Daisuke Maeda and Akifumi Matsuyama and James McBlane and Tomohiro Morio and John Petricciani and Mahendra Rao and Anthony Ridgway and Daisaku Sato and Yoji Sato and Glyn Stacey and Norihisa Sakamoto and Trouvin, {Jean Hugues} and Akihiro Umezawa and Masayuki Yamato and Kazuo Yano and Hiroyuki Yokote and Kentaro Yoshimatsu and Pierrette Zorzi-Morre",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.biologicals.2015.07.009",
language = "English",
volume = "43",
pages = "283--297",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "5",

}

Hayakawa, T, Aoi, T, Bravery, C, Hoogendoorn, K, Knezevic, I, Koga, J, Maeda, D, Matsuyama, A, McBlane, J, Morio, T, Petricciani, J, Rao, M, Ridgway, A, Sato, D, Sato, Y, Stacey, G, Sakamoto, N, Trouvin, JH, Umezawa, A, Yamato, M, Yano, K, Yokote, H, Yoshimatsu, K & Zorzi-Morre, P 2015, 'Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products', Biologicals, vol. 43, no. 5, pp. 283-297. https://doi.org/10.1016/j.biologicals.2015.07.009

Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products. / Hayakawa, Takao; Aoi, Takashi; Bravery, Christopher; Hoogendoorn, Karin; Knezevic, Ivana; Koga, Junichi; Maeda, Daisuke; Matsuyama, Akifumi; McBlane, James; Morio, Tomohiro; Petricciani, John; Rao, Mahendra; Ridgway, Anthony; Sato, Daisaku; Sato, Yoji; Stacey, Glyn; Sakamoto, Norihisa; Trouvin, Jean Hugues; Umezawa, Akihiro; Yamato, Masayuki; Yano, Kazuo; Yokote, Hiroyuki; Yoshimatsu, Kentaro; Zorzi-Morre, Pierrette.

In: Biologicals, Vol. 43, No. 5, 01.09.2015, p. 283-297.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products

AU - Hayakawa, Takao

AU - Aoi, Takashi

AU - Bravery, Christopher

AU - Hoogendoorn, Karin

AU - Knezevic, Ivana

AU - Koga, Junichi

AU - Maeda, Daisuke

AU - Matsuyama, Akifumi

AU - McBlane, James

AU - Morio, Tomohiro

AU - Petricciani, John

AU - Rao, Mahendra

AU - Ridgway, Anthony

AU - Sato, Daisaku

AU - Sato, Yoji

AU - Stacey, Glyn

AU - Sakamoto, Norihisa

AU - Trouvin, Jean Hugues

AU - Umezawa, Akihiro

AU - Yamato, Masayuki

AU - Yano, Kazuo

AU - Yokote, Hiroyuki

AU - Yoshimatsu, Kentaro

AU - Zorzi-Morre, Pierrette

PY - 2015/9/1

Y1 - 2015/9/1

N2 - The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document.Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted.Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.The conference concluded that most of the current regulatory framework is appropriate for cell therapy, but there are some areas where the application of the requirements for traditional biologicals is inappropriate. In addition, it was agreed that there is a need for international consensus on core regulatory elements, and that one of the major international organizations should take the lead in formulating such a consensus document.

AB - The regulation of human cell therapy products is a key factor in their development and use to treat human diseases. In that regard, there is a recognized need for a global effort to develop a set of common principles that may serve to facilitate a convergence of regulatory approaches to ensure the smooth and efficient evaluation of products. This conference, with experts from regulatory agencies, industry, and academia, contributed to the process of developing such a document.Elements that could form a minimum consensus package of requirements for evaluating human cell therapy products were the overall focus of the conference. The important regulatory considerations that are unique to human cell therapy products were highlighted.Sessions addressed specific points that are different from those of traditional biological/biotechnological protein products. Panel discussions complemented the presentations.The conference concluded that most of the current regulatory framework is appropriate for cell therapy, but there are some areas where the application of the requirements for traditional biologicals is inappropriate. In addition, it was agreed that there is a need for international consensus on core regulatory elements, and that one of the major international organizations should take the lead in formulating such a consensus document.

UR - http://www.scopus.com/inward/record.url?scp=84941314513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941314513&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2015.07.009

DO - 10.1016/j.biologicals.2015.07.009

M3 - Article

VL - 43

SP - 283

EP - 297

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 5

ER -